ADFORM
29.9.2020 12:20:14 CEST | Business Wire | Press release
Adform , the only independent global ad management platform covering all aspects of the digital campaign lifecycle, today introduced its new product suite: Adform FLOW. Intuitively designed to make it easier for marketers to plan, buy and activate media, Adform FLOW has everything they need in one easy-to-use platform: DSP, DMP, SSP, DCO and ad server. Through exceptional user experience and enhanced human/machine collaboration, Adform FLOW provides augmented intelligence to amplify business results.
Features of Adform FLOW include:
- Seamless and integrated User Experience, across all aspects of the campaign workflow and all digital media channels
- SaaS technology, which provides increased control and flexibility; including a modular and open API approach, coupled with the ability to control costs through license-based fees
- First-party identity-ready, setup for privacy compliance and a post-cookie world
- Media-neutrality, with no media or data ownership, and therefore no conflicts
Adform research, conducted in partnership with Dynata and surveying more than 1,000 marketers, shows almost three-quarters of modern marketers (74%) want a single dashboard to manage campaigns efficiently, with top benefits cited as data optimisation, cost efficiencies and control.
Now, more than three years in the making and building on Adform’s two decades of innovation, Adform FLOW is enterprise technology built for modern marketing: independent and integrated, giving marketers enhanced control over their own data, that they have not been able to realise through previous solutions. It is configurable, transparent and secure, enabling seamless management of campaigns.
Digital marketers have long struggled with the inefficiencies presented by the myriad of martech and adtech solutions they deploy, and today’s economic realities make the push for efficiency that much more urgent. Some companies have operated within walled gardens; others have sought out best-of-breed technologies and patched together point solutions that fail to work well together. Adform FLOW provides the feature richness of a complex point solution setup, with the scale, ease of use and efficiency of walled gardens.
Samir Shah, Managing Partner – Data, Technology & Programmatic at Zenith said: "I have been impressed at how Adform has continued to develop its platform, the efficiency gains reported are significant. Via their solutions I can see strategic benefits, particularly during a time of complexity in the market being aligned to the future of first-party IDs, and being able to differentiate is key.”
“Modern marketers need a complete solution that is customisable to their particular needs. We are certain that we can add significant value to our clients by enabling them to do more than they've been able to do before,” said Troels Jensen, CEO of Adform. “As the only independent fully integrated marketing platform, Adform offers transparency, privacy, and ownership of data. By addressing these challenges, Adform's clients benefit from Adform FLOW's unique architecture and are able to secure significantly stronger results.”
About Adform
Adform is the only global, independent and fully integrated advertising platform built for modern marketing. Its unique enterprise technology – Adform FLOW – harnesses superior user experience and a scalable, modular and open architecture, to enable seamless management of the whole campaign lifecycle. It provides clients with enhanced control and transparency across their advertising operations, including ownership of all data from their campaigns. Since 2002, Adform has developed technology to enhance human/machine collaboration and deliver augmented intelligence, thereby amplifying business results for its clients around the world.
For more information, please visit: www.adform.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20200929005513/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex to Acquire Crinetics Pharmaceuticals6.7.2026 22:04:00 CEST | Press release
- Crinetics adds potential best-in-class commercialized and Phase 3 endocrinology assets with ~$5 billion peak sales opportunity to Vertex’s portfolio - - PALSONIFY®, Crinetics’ recently launched, first and only, once-daily oral therapy for adults with acromegaly has demonstrated strong and growing early uptake - - Atumelnant, a once-daily oral adrenocorticotropic hormone (ACTH) receptor antagonist in Phase 3 development for congenital adrenal hyperplasia (CAH), has shown unique and transformative potential to both normalize androgen levels and enable management of patients with physiologic levels of glucocorticoids, the true goal of CAH management; atumelnant has also demonstrated therapeutic potential in patients with Cushing’s syndrome - - Acquisition adds to Vertex’s innovation pipeline, accelerates Vertex’s revenue growth and enhances long-term earnings profile - - Vertex to host investor call today, July 6 at 4:30 p.m. ET - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and C
Ciauru Wins the Second Edition of the Reply AI Music Contest, the International Competition Dedicated to Experimentation Across AI, Music and Live Performance6.7.2026 20:30:00 CEST | Press release
The winner was announced on the Kappa FuturFestival stage, following the performances of the five finalists selected by the international jury.German duo PARAFRAME & Avis Vox received the special Reply AI Studios Grand Prix award. The second edition of the Reply AI Music Contest, the international competition created by Reply to explore new forms of expression combining artificial intelligence, music and live performance, concluded with the announcement of the winner on the Nova Stage powered by Reply during Kappa FuturFestival. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706007611/en/ The second edition of the Reply AI Music Contest, the international competition created by Reply to explore new forms of expression combining artificial intelligence, music and live performance, concluded with the announcement of the winner on the Nova Stage powered by Reply during Kappa FuturFestival First place went to Ciauru, the stag
Rimini Street to Report Second Quarter 2026 Financial Results on July 30, 20266.7.2026 15:00:00 CEST | Press release
Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced it will report earnings after market close on July 30, 2026. The company will host a conference call and webcast on that date to discuss the second quarter 2026 results and the second half 2026 outlook at 5:00 p.m. Eastern / 2:00 p.m. Pacific time. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706560476/en/ Rimini Street to Report Second Quarter 2026 Financial Results on July 30, 2026 A live webcast of the event will be available on Rimini Street’s Investor Relations site via the Rimini Street IR events link and directly via the webcast link. Dial-in participants can access the conference by dialing 1-800-836-8184. A replay of the webcast will be available for one year following the event. About Rimini Street, Inc. Rimini Street, Inc. (Nasda
Orion and Shilpa Medicare Expand Partnership to Develop and Supply Nivolumab Biosimilar for Europe6.7.2026 15:00:00 CEST | Press release
Shilpa Medicare Limited announced that its wholly owned subsidiary, Shilpa Biologicals Private Limited, has entered into a co-development and supply agreement with Orion Corporation for intravenous (IV) nivolumab biosimilar referencing one of the world’s most widely used cancer immunotherapies to widen patient access across Europe. Nivolumab helped usher in the era of immuno-oncology, transforming the outlook for patients with cancers such as melanoma and lung cancer. As the originator approaches loss of exclusivity in Europe, this partnership aims to put a high-quality, EU-GMP-manufactured nivolumab biosimilar within reach of more patients, reducing healthcare burden. In 2025, Nivolumab recorded sales of approximately USD4.1 billion (Source: IQVIA/IMS) Europe — underscoring the scale of the opportunity. Under the agreement, Orion will hold the exclusive rights to register, market, distribute and sell the nivolumab biosimilar across Europe. Shilpa Biologicals will lead product developm
No-Loss Trading Platform UpsideOnly Surpasses 100,000 Users Within Weeks of Launch6.7.2026 14:48:00 CEST | Press release
Rapid growth shows strong demand for a new trading model where users can make market predictions without risking their own capital Perpetuals.com Ltd (Nasdaq: PDC), today announced that UpsideOnly, its risk-free trading and market prediction platform, has seen a surge in new user sign-ups, surpassing the important milestone of 100,000 traders within weeks of its launch on May 19. UpsideOnly lets users make predictions about where global equity, commodity, forex, and crypto markets are heading without ever placing a real trade themselves. Perpetuals uses its own capital to trade on the strongest signals identified by its proprietary AI. If those trades win, Perpetuals shares the profits with the users who helped generate the signal. If the trade doesn’t make money, users lose nothing. Reaching 100,000 users so quickly after launching is a reflection of the enormous demand for a platform that flips the traditional retail trading model on its head, with early platform data showing strong
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
